electroCore, Inc.
(NASDAQ: ECOR)
Market Cap: $80M
1Q26 Cash: $8.8M
2026E Revenue: $41.6M
EV/2026E Revenue: ~1.7x
Bioelectronic Medicine for Chronic Neurological Conditions
electroCore, Inc. (NASDAQ: ECOR) is a commercial-stage bioelectronic medicine company using non-invasive neuromodulation to address chronic pain, headache, and wellness conditions.
Migraine Is One of the Most Prevalent Neurological Conditions in the World
U.S. adults living with migraine or severe headache
A chronic neurological condition with recurring, lifelong treatment needs
People worldwide living with migraine (2021)
(GBD 2021 burden estimates)
U.S. migraine drugs market
Reflects chronic use rather than one-time treatment
The Limitation Isn't Efficacy — It's Chronic Use
Most current treatment approaches rely on pharmacologic therapies.
While often effective in the short term, many are limited by:
Side effects that limit sustained use
Drug–drug interactions in polypharmacy patients
Declining adherence over time
Chronic neurological conditions create recurring, long-duration treatment demand, favoring therapies designed for frequent, sustained use.
Neuromodulation Is Becoming a Third Treatment Modality…
Historically, neuromodulation required surgical implants and specialized care.
Advances in bioelectronic technology now allow non-invasive neuromodulation, enabling:
- At-home use
- Repeat daily therapy
- Broad patient access
electroCore Built a Commercial Platform Around This Shift
electroCore's technology is based on non-invasive vagus nerve stimulation (nVNS).
Delivered through the skin at the neck, nVNS targets a major neurological pathway involved in pain processing, inflammation, and autonomic regulation — without implants or systemic drug exposure.
One Neurological Pathway, Multiple End Markets
electroCore applies the same core technology across distinct markets:
gammaCore®
FDA-cleared for the prevention and acute treatment of migraine and cluster headache, gammaCore is a handheld, non-invasive neuromodulation therapy that delivers vagus nerve stimulation through the skin at the neck.
Quell®
FDA-authorized for fibromyalgia symptoms, Quell® is a non-invasive neuromodulation therapy designed for regular use to help manage chronic pain.
Truvagaâ„¢
Direct-to-consumer neuromodulation device designed to support stress reduction and sleep through non-invasive vagus nerve stimulation.
TAC-STIMâ„¢
A non-invasive neuromodulation solution developed with the U.S. Air Force to support attention, fatigue management, and cognitive performance in high-demand operational environments.
This Is Already a Business, Not a Hypothesis
Proof of Commercial Execution
Solid Revenue Growth
55% Five-year revenue CAGR
Strong Gross Margins
85% Gross Margins
Expanding Commercially
VA, NHS, and consumer channels
Consistent Top-line Growth Since 2019
*Revenue since 2019, ($M)